[go: up one dir, main page]

MX2010011464A - 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. - Google Patents

2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.

Info

Publication number
MX2010011464A
MX2010011464A MX2010011464A MX2010011464A MX2010011464A MX 2010011464 A MX2010011464 A MX 2010011464A MX 2010011464 A MX2010011464 A MX 2010011464A MX 2010011464 A MX2010011464 A MX 2010011464A MX 2010011464 A MX2010011464 A MX 2010011464A
Authority
MX
Mexico
Prior art keywords
syk
methods
jak kinase
carboxamides
pyrimidin
Prior art date
Application number
MX2010011464A
Other languages
English (en)
Other versions
MX353206B (es
Inventor
Shawn M Bauer
Zhaozhong J Jia
Yonghong Song
Qing Xu
Mukund Mehrotra
Jack W Rose
Wolin Huang
Chandrasekar Venkataramani
Anjali Pandey
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Priority claimed from PCT/US2009/002420 external-priority patent/WO2009145856A1/en
Publication of MX2010011464A publication Critical patent/MX2010011464A/es
Publication of MX353206B publication Critical patent/MX353206B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se dirige a compuestos de la Fórmula I-II y tautómeros, sales o estereoisómeros farmacéuticamente aceptables de la misma que son inhibidores de syk y/o JAK quinasas. La presente invención también se dirige a intermediarios usados para realizar dichos compuestos, a la preparación de dicho compuesto, composiciones farmacéuticas que contienen dicho compuesto, métodos de inhibición de syk y/o JAK quinasa, métodos para la inhibición de agregación de plaquetas, y métodos para evitar o tratar una cantidad de enfermedades mediadas, al menos en parte, por la actividad syk y/o JAK quinasa, como por ejemplo trombosis y Linfoma no- Hodgkin.
MX2010011464A 2008-04-16 2009-04-16 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. MX353206B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US4539908P 2008-04-16 2008-04-16
US4541708P 2008-04-16 2008-04-16
US4540608P 2008-04-16 2008-04-16
US12034408P 2008-12-05 2008-12-05
US12034108P 2008-12-05 2008-12-05
US12034808P 2008-12-05 2008-12-05
PCT/US2009/002420 WO2009145856A1 (en) 2008-04-16 2009-04-16 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors

Publications (2)

Publication Number Publication Date
MX2010011464A true MX2010011464A (es) 2014-06-16
MX353206B MX353206B (es) 2018-01-08

Family

ID=43570275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011464A MX353206B (es) 2008-04-16 2009-04-16 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.

Country Status (18)

Country Link
AU (1) AU2009251863B2 (es)
BR (1) BRPI0910560B8 (es)
CO (1) CO6331433A2 (es)
CY (1) CY1118559T1 (es)
DK (1) DK2321283T3 (es)
ES (1) ES2597441T3 (es)
GT (1) GT201000298A (es)
HK (1) HK1158179A1 (es)
HU (1) HUE031638T2 (es)
IL (3) IL208637A (es)
LT (1) LT2321283T (es)
MX (1) MX353206B (es)
NI (1) NI201000176A (es)
NZ (1) NZ589314A (es)
PL (1) PL2321283T3 (es)
PT (1) PT2321283T (es)
SI (1) SI2321283T1 (es)
ZA (1) ZA201007045B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20130099040A (ko) 2010-08-10 2013-09-05 셀진 아빌로믹스 리서치, 인코포레이티드 Ｂｔｋ 억제제의 베실레이트 염
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
EP4306172A4 (en) * 2021-03-09 2025-03-26 Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd USE OF A COMPOUND CONTAINING A TRICYCLIC HETEROARYL
CN114196651B (zh) * 2021-12-15 2023-06-30 中国林业科学研究院亚热带林业研究所 D6蛋白激酶d6pkl2的新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432963B1 (en) * 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
US7449456B2 (en) * 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
WO2008009458A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors

Also Published As

Publication number Publication date
BRPI0910560B8 (pt) 2023-03-21
CY1118559T1 (el) 2017-07-12
IL274522A (en) 2020-06-30
BRPI0910560B1 (pt) 2023-01-24
AU2009251863A1 (en) 2009-12-03
PL2321283T3 (pl) 2017-01-31
ES2597441T3 (es) 2017-01-18
AU2009251863A2 (en) 2011-06-09
NI201000176A (es) 2011-08-08
LT2321283T (lt) 2016-12-12
PT2321283T (pt) 2016-10-19
HK1158179A1 (zh) 2012-07-13
IL251655B (en) 2020-05-31
NZ589314A (en) 2012-10-26
IL251655A0 (en) 2017-06-29
HUE031638T2 (en) 2017-07-28
GT201000298A (es) 2014-05-07
MX353206B (es) 2018-01-08
IL208637A (en) 2017-04-30
IL208637A0 (en) 2010-12-30
ZA201007045B (en) 2012-08-29
CO6331433A2 (es) 2011-10-20
AU2009251863B2 (en) 2014-09-25
DK2321283T3 (en) 2016-10-31
BRPI0910560A2 (pt) 2021-04-27
SI2321283T1 (sl) 2017-01-31

Similar Documents

Publication Publication Date Title
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
NZ589315A (en) 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
MX353206B (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
WO2009131687A3 (en) Inhibitors of protein kinases
WO2009136995A3 (en) 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
JO3398B1 (ar) مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
WO2012061418A3 (en) Benzamides and nicotinamides as syk modulators
PH12013502463A1 (en) Trpv4 antagonists
EP3363797A8 (en) Oral dosage form of apoptosis signal-regulating kinase inhibitors
GEP20156285B (en) Compounds and compositions as trk inhibitors
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PH12014500137A1 (en) Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2012061428A3 (en) Nicotinamides as jak kinase modulators
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
MX363551B (es) Compuestos derivados de pirazina como inhibidores de cinasa.
MX2011012631A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
TN2010000469A1 (en) 2-9 diamino pyrimidin 5 yl carboxamides as syk or jak kinases inhibitors
IN2013MU02611A (es)
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration